CA2879151C - Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof - Google Patents

Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof Download PDF

Info

Publication number
CA2879151C
CA2879151C CA2879151A CA2879151A CA2879151C CA 2879151 C CA2879151 C CA 2879151C CA 2879151 A CA2879151 A CA 2879151A CA 2879151 A CA2879151 A CA 2879151A CA 2879151 C CA2879151 C CA 2879151C
Authority
CA
Canada
Prior art keywords
formula
compound
substituted
occurs
enantiomerically pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2879151A
Other languages
English (en)
French (fr)
Other versions
CA2879151A1 (en
Inventor
John F. Traverse
Chengmin Zhang
Gregg B. Feigelson
Benjamin M. Cohen
William W. Leong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Priority to CA3108974A priority Critical patent/CA3108974C/en
Publication of CA2879151A1 publication Critical patent/CA2879151A1/en
Application granted granted Critical
Publication of CA2879151C publication Critical patent/CA2879151C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2879151A 2012-08-09 2013-08-08 Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof Active CA2879151C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3108974A CA3108974C (en) 2012-08-09 2013-08-08 Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261681477P 2012-08-09 2012-08-09
US61/681,477 2012-08-09
PCT/US2013/054099 WO2014025978A1 (en) 2012-08-09 2013-08-08 Processes for the preparation of (s)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3108974A Division CA3108974C (en) 2012-08-09 2013-08-08 Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof

Publications (2)

Publication Number Publication Date
CA2879151A1 CA2879151A1 (en) 2014-02-13
CA2879151C true CA2879151C (en) 2021-03-30

Family

ID=49035933

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2879151A Active CA2879151C (en) 2012-08-09 2013-08-08 Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof
CA3108974A Active CA3108974C (en) 2012-08-09 2013-08-08 Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3108974A Active CA3108974C (en) 2012-08-09 2013-08-08 Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof

Country Status (19)

Country Link
US (2) US9309220B2 (enExample)
EP (2) EP2882736B1 (enExample)
JP (1) JP6444866B2 (enExample)
KR (1) KR20150041650A (enExample)
CN (1) CN104718202B (enExample)
AU (1) AU2013299559B2 (enExample)
BR (1) BR112015002183A2 (enExample)
CA (2) CA2879151C (enExample)
CR (1) CR20150051A (enExample)
EC (1) ECSP15004585A (enExample)
ES (2) ES2914876T3 (enExample)
HK (1) HK1211577A1 (enExample)
IL (1) IL236925A0 (enExample)
IN (1) IN2015DN00845A (enExample)
MX (2) MX2015001633A (enExample)
PH (1) PH12015500214A1 (enExample)
RU (1) RU2015108057A (enExample)
SG (1) SG11201500984QA (enExample)
WO (1) WO2014025978A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
EP2699091B1 (en) 2011-03-28 2017-06-21 DeuteRx, LLC 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
AU2014205043B2 (en) 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
AU2014236597A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
MX2020002010A (es) 2017-08-21 2020-07-13 Celgene Corp Procesos para la preparacion de 4,5-diamino-5-oxopentanoato de (s)-terc-butilo.
CA3114401A1 (en) 2018-10-01 2020-04-09 Celgene Corporation Combination therapy for the treatment of cancer
CN110194760B (zh) * 2019-05-27 2021-08-17 浙江农林大学暨阳学院 制备3-亚苄基-2-（7’-喹啉）-2,3-二氢-异吲哚-1-酮类化合物的方法
KR20220110243A (ko) * 2019-12-02 2022-08-05 셀진 코포레이션 암의 치료를 위한 요법
CN113896711A (zh) 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 杂环类免疫调节剂
US20260098035A1 (en) 2022-09-20 2026-04-09 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
CN121002005A (zh) * 2023-04-11 2025-11-21 上海科胜药物研发有限公司 一种芳基甲氧基异吲哚啉衍生物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
NZ554068A (en) * 2004-09-03 2009-07-31 Celgene Corp Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo-lines
PL1907373T3 (pl) * 2005-06-30 2013-05-31 Celgene Corp Sposób wytwarzania związków 4-amino-2-(2,6-diokso-piperydyn-3-ylo)izoindolino-1,3-dionu
CA2681633C (en) 2007-03-20 2018-01-09 Celgene Corporation 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
SG183257A1 (en) * 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US8877932B2 (en) 2010-03-08 2014-11-04 Natco Pharma Limited Anhydrous lenalidomide form-I
US9085551B2 (en) 2012-02-21 2015-07-21 Celgene Corporation Solid forms of 3-(4-nitro-1-oxisoindolin-2-yl)piperidine-2,6-dione

Also Published As

Publication number Publication date
JP6444866B2 (ja) 2018-12-26
HK1211577A1 (en) 2016-05-27
ECSP15004585A (es) 2015-12-31
EP3466942A1 (en) 2019-04-10
MX385058B (es) 2025-03-14
US9975872B2 (en) 2018-05-22
EP2882736B1 (en) 2019-01-09
ES2914876T3 (es) 2022-06-17
IN2015DN00845A (enExample) 2015-06-12
BR112015002183A2 (pt) 2017-07-04
CA2879151A1 (en) 2014-02-13
AU2013299559A1 (en) 2015-02-05
CA3108974C (en) 2023-04-04
WO2014025978A1 (en) 2014-02-13
ES2712652T3 (es) 2019-05-14
US20160251333A1 (en) 2016-09-01
US20140046058A1 (en) 2014-02-13
US9309220B2 (en) 2016-04-12
KR20150041650A (ko) 2015-04-16
CA3108974A1 (en) 2014-02-13
RU2015108057A (ru) 2016-09-27
PH12015500214A1 (en) 2015-04-27
CR20150051A (es) 2015-05-11
SG11201500984QA (en) 2015-04-29
IL236925A0 (en) 2015-03-31
MX2015001633A (es) 2015-04-08
JP2015524481A (ja) 2015-08-24
EP2882736A1 (en) 2015-06-17
AU2013299559B2 (en) 2017-08-17
CN104718202A (zh) 2015-06-17
EP3466942B1 (en) 2022-04-20
CN104718202B (zh) 2018-11-20

Similar Documents

Publication Publication Date Title
CA3108974C (en) Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof
JP6392436B2 (ja) 置換された５−フルオロ−１ｈ−ピラゾロピリジン類を製造するための方法
US4923986A (en) Derivatives of physiologically active substance K-252
KR102613409B1 (ko) 항암제인 l-((4-(4-플루오로-2-메틸-lH-인돌-5-일옥시)-6-메톡시퀴놀린-7-일옥시)메틸)시클로프로판아민, 이의 결정형 및 이의 염의 제조방법
CA2961984C (en) Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines
KR20100116206A (ko) Ｈｓｐ90 저해제로서의 옥심 유도체
WO2015049629A1 (en) Imidazoquinoline compounds as bromodomain inhibitors
WO2022214645A1 (en) Processes and intermediates for the preparation of relugolix
TWI888947B (zh) 用於製備可溶性鳥苷酸環化酶刺激劑之新穎方法及中間物
KR20170132278A (ko) 암 치료에 유용한 1-(사이클로) 알킬 피리딘-2-온의 트리사이클릭 융합 유도체
EP2928472A1 (en) Process for making reverse transcriptase inhibitors
CN1914213B (zh) 噻唑并嘧啶的制备方法
JP2003504364A (ja) ベンゾフラン誘導体
KR20010090193A (ko) 피리미디논 화합물 및 이의 염의 제조방법
JP2004503543A (ja) １，２，４−トリアゾリン−５−オン誘導体の製造方法
JP2016172755A (ja) 抗ウイルス化合物およびその有用な中間体の調製方法
WO2016023522A2 (en) Substituted phosphoramidate compounds and uses thereof
JP2025512951A (ja) Ｇｐｒ３５調節因子及びその使用
JP2009504720A (ja) 農薬として使用されるベンゾキサゾール誘導体の調製のための化学的方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180808

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250702

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250702

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260701

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260702